BioCatalystWatch
CRNXWorkspace / CRNX / OverviewCompany library
Crinetics Pharmaceuticals, Inc. logo

Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. (CRNX)

Website

Price
Market cap
Next catalystExpected 2026atumelnant · Trial initiationCompany presentation ↗
Cash

Chart & Events

Candle interval

Core Clinical

Atumelnant (CRN04894)

MC2R (ACTH receptor)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

paltusotine (PALSONIFY)

SST2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

CRN09682

SST2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

PTH Antagonist

PTH

Upcoming / outlook

Oral GIP Nonpeptide

PreINDP1P2P3FilingApproved
Upcoming / outlook

Oral GLP-1 Nonpeptide

GLP-1R

PreINDP1P2P3FilingApproved
Upcoming / outlook

SST3 agonist program

SST3

PreINDP1P2P3FilingApproved
Upcoming / outlook

TSH antagonist program

TSH

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Atumelnant (CRN04894)

MC2R (ACTH receptor)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

paltusotine (PALSONIFY)

SST2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

TSH antagonist program

TSH

PreINDP1P2P3FilingApproved
Upcoming / outlook

Oral GIP Nonpeptide

PreINDP1P2P3FilingApproved
Upcoming / outlook

Oral GLP-1 Nonpeptide

GLP-1R

PreINDP1P2P3FilingApproved
Upcoming / outlook

CRN09682

SST2

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Other pipelines

CRN12755

TSHR

PreINDP1P2P3FilingApproved
Upcoming / outlook

CRN12755

TSHR

PreINDP1P2P3FilingApproved
Upcoming / outlook

Oral GIP Nonpeptide

PreINDP1P2P3FilingApproved

Approved / commercial

paltusotine (PALSONIFY)

SST2

Approved

PreINDP1P2P3FilingApproved

History / paused

MC2R (ACTH receptor)

PreINDP1P2P3FilingApproved

SST5

PreINDP1P2P3FilingApproved

SST2

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing


PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing


PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

CRNX PR & News

PR & News

CRNX SEC archive